June 30, 2022
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
May 12, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
May 5, 2022
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
April 8, 2022
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
March 31, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
Displaying 1 - 10 of 18
